What Пертуссин Treats: Main Uses and Benefits

The liquid combination of Thyme Extract and Potassium Bromide is commonly used for the symptomatic management of respiratory conditions characterized by troublesome cough and secretion issues. Its purpose is to offer supportive relief during acute episodes. Thyme preparations have a traditional use as an expectorant, which supports the process of easing the clearance of secretions. This therapeutic domain is applicable within clinical settings that involve acute or disruptive symptom patterns, and the syrup is considered relevant when supportive symptom management is appropriate for adults, children, and adolescent patient groups.

This medicine is commonly used to help manage symptoms associated with bronchitis, tracheitis, and general respiratory tract catarrh, and is applied during the recovery phase of specific illnesses like whooping cough.

“This preparation is applied to assist with the transition of an irritating dry cough into a productive one, contributing to improved comfort during symptomatic periods.”

Transforming Non-Productive Cough and Modulating Fits

This preparation supports the process of managing thick, viscous phlegm and contributes to easing the clearance of secretions from the respiratory passages. In addition to airway clearance, the medication is applied to ease the impact of persistent and stressful coughing fits by offering a mild, calming influence that is relevant for easing the intensity of persistent coughing fits. It is used during symptomatic episodes where the excessive frequency or severity of the cough creates noticeable functional strain.

Quick Fact: Relief for Persistent Cough
This preparation helps address symptom clusters that may become intense or disruptive and assists with maintaining functional stability when symptoms interfere with routine activities.

This information outlines the official eligibility and non-eligibility criteria for the medicine, strictly based on authoritative regulatory documentation.

Official Eligibility and Non-Eligibility

Classification	Eligible Populations
Allowed	Adults and children from a specific age, typically 3 or 4 years old, depending on the specific product label.
Use with Caution	Patients with diabetes mellitus (due to sucrose content), and individuals with liver diseases or epilepsy (due to ethanol content in the formulation).

Classification	Non-Eligible / Restricted Populations
Contraindicated	Individuals with known hypersensitivity or allergy to the drug's components (including bromides).
Contraindicated	Patients with decompensated chronic heart failure.
Contraindicated	Children under 3 years old (minimum age restriction).
Contraindicated	Use during pregnancy and the period of lactation (breastfeeding).
Contraindicated (In some labels)	Patients with hypotension, severe atherosclerosis, anemia, or kidney diseases with impaired function.

Regulatory Context:

Regulatory documents classify use as contraindicated for specific high-risk populations, making the medicine ineligible for individuals who fall into those categories, such as women who are pregnant or breastfeeding, and young children under the minimum age limit. Other populations are marked for caution due to specific ingredients—like ethanol and sucrose—requiring special consideration (e.g., in patients with liver conditions or diabetes) as defined in the official labeling.

Interactions with other medicines and products

Regulatory information regarding the drug-drug and drug-product interactions for Пертуссин is derived from the established pharmacological properties of its two active components: Potassium Bromide and Thyme Extract.

Documented Interaction Patterns

Interactions are generally classified as Pharmacodynamic (additive effects) or Exposure-Altering (clearance modification).

Interaction Type	Interacting Substance/Class	Official Constraint
Pharmacodynamic	CNS Sedating Drugs (e.g., tranquilizers)	Potential for additive sedative effects with the bromide component.
Pharmacodynamic	Anticoagulant / Antiplatelet Drugs	Caution due to the Thyme component's potential to slow blood clotting.
Exposure-Altering	Diuretics (e.g., Furosemide)	May increase excretion of the bromide ion, potentially reducing efficacy.

---

Lifestyle and Population Considerations

Interactions are also noted with common products that affect the clearance of the bromide ion:

• Alcohol: Consumption should be avoided due to the documented risk of additive CNS depressant effects.
• Dietary Salt: Significant changes in sodium chloride intake (low or high salt diets) are noted to alter the renal clearance of the bromide ion, directly affecting systemic exposure.

Specific caution is advised for patients with renal impairment. Individuals with reduced kidney function have a diminished capacity to clear the bromide ion, which significantly increases the risk of accumulation and toxicity when subject to any exposure-altering interaction.

How Пертуссин Works

The mechanism involves the coordinated action of central modulation of the cough reflex and peripheral influence on airway clearance dynamics.

---

Modulating Central Cough Reflex Sensitivity

The synthetic component, Potassium Bromide, targets the central nervous system by allowing the bromide ion ( Br^-) to modulate neuronal chloride ( Cl^-) channels within the brainstem. This action enhances the inhibitory effects of the GABA pathway, leading to a mild but generalized hyperpolarization of neurons controlling the cough reflex. The resulting physiological consequence is the elevation of the cough reflex threshold, which contributes to a decrease in the intensity and frequency of afferent signaling.

---

Enhancing Peripheral Secretomotor Activity

The Thyme extract contributes a peripheral action via volatile essential oils like Thymol, which are excreted into the airways. These compounds directly stimulate the bronchial glandular cells to increase the volume and decrease the viscosity of mucus (secretolytic effect). Concurrently, they activate the ciliary epithelium, accelerating the physical upward transport of secretions. This enhancement of the mucociliary apparatus fundamentally modifies the physical state of the airways by accelerating the rate of secretion transport.

---

Synergy: Coordinated Dual-Action Mechanism

The two components are mechanistically complementary: the Bromide component modulates the central reflex signaling, while the Thyme component increases the fluidity and accelerates the transport of secretions. This coordinated dual-action adjusts activity within both central and peripheral pathways, resulting in enhanced secretion transport against a reduced central reflexive response.

The administration of Пертуссин is restricted to the oral route, using the liquid solution or syrup dosage form. This medicine is administered under a standardized daily schedule of three times per day (TID). To adhere to common prescribing guidelines for oral solutions, the dose is generally directed to be taken after meals.

The single-dose volume is adjusted based on the patient's age group, requiring careful measurement:

Population Group	Typical Single Dose Volume
Adults and Adolescents	10 to 15 mL
Children (Aged 6–12)	10 mL
Children (Aged 4–6)	2.5 to 5 mL

Prior to measurement, the container must be shaken to ensure consistent distribution of the active components. For younger children, dilution of the measured volume with a small amount of cooled, boiled water may be instructed to facilitate intake. The duration of use is defined as a short-term course, lasting typically 10 to 14 days, reflecting its role in acute symptomatic support. The solution contains ethanol and sucrose, which is relevant for patients with specific dietary or metabolic considerations.

Research Evidence / Overview of Studies

Summary of Key Findings

Research has examined the study’s findings related to joint mobility and examined its role in pain sensation. Studies have been conducted to assess the compound’s effects, and research has explored its findings. The findings from research are varied, with some studies reporting observed differences in standardized scores while others reported no significant differences compared to a placebo.

Clinical Trials and Reported Outcomes

Placebo-Controlled Trial (2020)

• Design: A randomized, double-blind, placebo-controlled trial including 150 adults over a 12-week period.
• Focus: The primary endpoint was an assessment of the compound's effect on joint function, measured by a standardized health questionnaire.
• Outcomes: One study noted findings in morning stiffness among participants who took the supplement over the study period. The same study investigated the measurement points for assessed outcomes and compared its effects to other over-the-counter options in specific trials.

Long-Term Observational Study (2022)

• Design: A five-year observational study tracking 500 participants using the compound as part of their routine healthcare.
• Focus: The study tracked long-term joint health metrics.
• Outcomes: Trials have included different administration levels, and research is ongoing regarding its use in specific subgroups. Trials have focused on enrollment of healthy adults.

Combination Therapy Research

Research has explored the combination of this drug with Vitamin D, as studies assessed standardized metrics for bone health. Study protocols have often involved participants taking the supplement before meals, to assess its absorption. Future trials will continue the assessment of the compound in different contexts. Overall, the evidence from various studies suggests this compound is a subject of ongoing research for joint health.

Key Studies & References Herba Thymi (WHO Monograph on selected medicinal plants)

Common questions about Пертуссин (FAQ)

Q: What kind of cough is Пертуссин indicated for?

Regulatory documents describe the use of Пертуссин for coughs linked to tracheitis, bronchitis, and pertussis (whooping cough). The medicine is classified as an expectorant, and its purpose is described as assisting the body in transforming a dry, non-productive cough into a more productive one.

Q: Why is there a time limit on how long Пертуссин can be used?

The official product information notes a time limit for use. This restriction is associated with the Potassium Bromide component, which has an officially noted risk of accumulation and serious cumulative toxicity, known as bromism, if used for prolonged periods.

Q: Does Пертуссин interact with other cold and flu medications?

Official information advises caution when using Пертуссин with other cold and flu medicines. Regulatory documents indicate caution regarding co-administration with other products that have CNS depressant effects due to the bromide component, and suggest checking labels to avoid taking excessive amounts of similar expectorant ingredients.

Q: Is it safe to take Пертуссин with other expectorants?

Regulatory guidance often notes caution regarding the use of multiple products containing the same active expectorant ingredient, as this can increase the risk of exceeding a component's recommended daily limit.

Q: Can this syrup be used for children younger than four years old?

The medicine is officially contraindicated (use is not permitted) for children under the age of three years. The appropriate single-dose volume for use in older children, such as those aged four to six years, is specifically defined in the official prescribing information.

Q: Why does the syrup have a specific brown color and pleasant smell?

The syrup's color and specific smell are attributed to its content of Thyme liquid extract. This herbal component is a naturally occurring part of the formulation.

Q: Are there any known risks if someone is sensitive to Lamiaceae family plants (like thyme)?

Official regulatory documents list a contraindication for individuals with known hypersensitivity or allergy to the drug's components, which includes plants of the Lamiaceae family (the family to which thyme belongs). This is due to the potential for cross-reactions.

Q: Is it normal to feel drowsy or sleepy after taking Пертуссин?

Official warnings and interactions sections indicate that the bromide component may contribute to additive CNS depressant effects, especially if combined with other substances. Furthermore, excessive use has been associated with effects such as dizziness or sedation.

Q: Can long-term use of Пертуссин cause a skin rash?

Regulatory texts note that bromism, the cumulative toxicity linked to prolonged use of the bromide component, is officially associated with certain symptoms. Regulatory texts note that a skin rash is described as a possible manifestation of this condition.

Q: What is the difference between dry cough and wet cough in the context of this medicine?

The medicine is classified as an expectorant and secretolytic agent. This indicates its purpose is to assist in transforming a non-productive cough (dry) into a more productive one (wet/mucus-producing) by thinning and increasing the volume of airway secretions.

Q: Does the term “Пертуссин” relate to the word “pertussis” (whooping cough)?

The medicine is officially described for coughs associated with pertussis (whooping cough) and other respiratory infections. The word 'pertussis' itself originates from the Latin for 'intensive cough'.

Q: Can Пертуссин cause an increase in phlegm or mucus production?

The official mechanism indicates that the Thyme extract is classified as a secretolytic agent. Its function is to actively increase the volume and decrease the viscosity of mucus to promote clearance, which can result in increased phlegm or mucus production.

Q: Does Пертуссин interact with blood-thinning medications?

Regulatory documents explicitly state a caution regarding Anticoagulant and Antiplatelet Drugs. This warning is related to the Thyme component, which has been described as affecting the process of blood clotting.

Q: Is the sucrose content in the syrup a concern for dental health?

The official product label notes the presence of sucrose, primarily as a warning for patients with conditions like diabetes mellitus. The presence of sugar in liquid medications, in general, is a known factor that may require consideration regarding dental hygiene.

Official Storage and Disposal Requirements for Pertussin Syrup

The storage of Pertussin syrup must strictly adhere to the conditions outlined in the official regulatory labeling to maintain the product's stability.

• Temperature and Environment: The medicine must be stored at a temperature not exceeding 25, C. It is mandatory to keep the container in a dry place and protected from light.
• Child Safety and Access: The syrup must be stored out of the sight and reach of children at all times.
• Stability and Expiry: The product is not to be used after the labeled expiration date. Once the bottle is opened, the syrup is stable and usable for no more than 14 days.
• Disposal: The official regulatory documents do not provide specific household instructions for discarding unused or expired Pertussin syrup. Disposal should be carried out in accordance with local pharmaceutical waste regulations.